Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15188955 | 0.80 | KMT2A (0.35) | — | |
| SCHEMBL27114624 | 0.79 | CYP1A2 (0.32) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL9968464 | 0.77 | GRIN2D (0.30) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL13827693 | 0.77 | — | — | |
| SCHEMBL368761 | 0.74 | USP2 (0.45) | CHRM2CHRM1 | |
| SCHEMBL26444547 | 0.73 | — | — | |
| SCHEMBL16903788 | 0.73 | KCNH2 (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL20396124 | 0.72 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL12212835 | 0.72 | KCNH2 (0.42) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL22847828 | 0.71 | GRIN2D (0.35) | HSD11B1GRIN2DGRIN3BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056865-B2 | Pyridine-2-derivatives as smoothened receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130210800-A1 | PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS | PFIZER INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | HSD11B1 3610/4885GRIN2D 4366/4885GRIN3B 4055/4885 |
| US-20130210800-A1 | PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS | SMO, EDNRB, RXFP1 | HSD11B1 3645/4885GRIN2D 1537/4885GRIN3B 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.